All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.
Categories
Recent Posts
CJC-1295 Peptide Research: GHRH Analog and Growth Hormone
Explore CJC-1295, a GHRH analog originally developed as an investigational compound. Studies have measured its effects on growth hormone and IGF-1 levels.
PP-TS1: GHRH Analog Research
PP-TS1 is a growth hormone-releasing hormone analog studied for its stability, GHRH-receptor pharmacology and GH/IGF-1 responses. A summary of the published literature.
Peptides and Aging Biology: A Research Overview
Peptides are gaining attention as research tools in aging biology. These short chains of amino acids regulate cellular repair, inflammation, and hormonal balance, processes that are studied in research on age-related conditions. Recent research has examined their interactions with aging mechanisms. This article explores peptides’ role in aging biology research and the challenges facing this field.
ARA 290 Peptide: From Erythropoietin to Neuropathy Research
Brief Overview/Summary
ARA 290, a nonhematopoietic peptide from erythropoietin's structure, activates the innate repair receptor and has been studied in models of tissue injury and neuropathic symptoms.
A non-hematopoietic peptide called ARA 290, designed based on erythropoietin's structure, can preferentially connect with the innate repair receptor responsible for performing tissue protection. ARA 290 administration has been examined in preclinical and clinical investigations on metabolic control and neuropathic symptoms.
EPO derivative structure of ARA 290 from study
The linear peptide ARA 290 has a molecular weight of 1257 Daltons and consists of 11 amino acids. Pyr is an abbreviation for pyroglutamic acid, and the sequence of amino acids is as follows: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. The figure that follows provides an illustration of the chemical structure of ARA 290.
Development background
Because of its natural function as a powerful anti-inflammatory cytokine, erythropoietin (EPO) has been explored in cardiovascular disease research. Nevertheless, the primary erythropoietic consequences of direct EPO administration, which include an increase in the mass of red blood cells and, as a consequence, an increased risk of thromboembolic outcomes, were found to be more detrimental than the potential areas of research interest of this approach. [2]. Consequently, the creation of ARA 290 (cibinetide) began.
This peptide is generated from the tissue's protective region of erythropoietin but does not possess any erythropoietic properties. By a heterodimeric receptor consisting of EPOR and CD131, the β common chemokine receptor ARA 290 plays a role in tissue protection by lowering inflammatory and fibrotic responses. This is accomplished by the formation of receptor complexes with the α receptor parts that are specific for GM-CSF, IL-3, and IL-5. [3]
Michael Brines stated that the 11-amino acid peptide ARA 290, which is the lead component of his development study, is now being evaluated across advanced studies of painful neurotoxicity and diabetes. Its effects on the balance between injury and repair have been examined in a variety of preclinical models of disease. [4]
Tissue protective properties
ARA 290 is a synthetic peptide that is generated from the tertiary structure of erythropoietin (EPO), which is a hormone that is primarily recognized for its function in the production of red blood cells. To study the tissue-protective properties of EPO without promoting erythropoiesis, this advanced peptide has been developed.
Studies conducted in both preclinical and clinical settings have examined the effects of ARA 290 on inflammatory processes, recovery, and injury in various organs and tissues.
Mechanism of Action of ARA 290 Peptide EPO Receptor Binding during Neuropathic Pain
EPO receptor binding
Erythropoietin's structure served as the inspiration for the creation of ARA 290. It accomplishes this by specifically engaging with the innate repair receptor, which is responsible for this tissue protection. Studies have reported reductions in apoptosis, also known as programmed cell death, and in inflammation as a result of this.
Inflammatory pathways
The actions of ARA 290 are achieved by the selective activation of the innate repair receptor (IRR), which is a heteromeric complex consisting of EPO receptor (EPOR) and β common receptor (βcR) subunits. Because of this particular contact, a chain reaction of signaling events is triggered, which studies have associated with anti-inflammatory, tissue-protective, and repair-related activity.
To modify the immune response, it has been demonstrated that ARA 290 can reduce the production of cytokines that promote inflammation while simultaneously raising the expression of mediators that inhibit inflammation. In addition to this, studies have examined its effect on the survival and function of numerous cell types, such as endothelial cells, heart muscle cells, and neurons, when they are subjected to stressful conditions.
Neuroprotective effects
ARA 290 was found to diminish allodynia in an exposure-dependent manner, which was accompanied by a reduction of the spinal microglia response. This finding suggests that there is a mechanistic connection between the inhibition of central inflammation that ARA 290 induces and the changes in neuropathic pain measures observed in the study. [6].
Research Evidence
In mouse cells, ARA-290 was associated with changes in tissue homeostasis through the regulation of signaling pathways that are associated with inflammation. Because persistent inflammation can cause damage to tissues and contribute to a variety of disorders, its regulation is especially important because of its potential health implications. The effect of ARA 290 on pro-inflammatory signaling pathways makes it relevant to research on disorders that involve the central nervous system, which is a region of the body in which inflammation frequently plays a significant role. [7]
When applied to a model of retinal ischemia, which is characterized by an inadequate supply of blood to the eye, ARA 290 was associated with longer cell survival and changes in blood vessel repair. According to these findings, ARA 290 is a research compound of interest in studies of retinal illnesses that include ischemia. A pilot study that is conducted with a double-masked design would be necessary in order to evaluate its effects and safety further. In individuals with retinal ischemia, a study of this nature could inform study protocols and the evaluation of the properties of research interest of ARA 290 [8].
In rats that had suffered a spinal cord injury, ARA 290 inhibited the production of spinal inflammatory mediators like CCL2, and studies measured reduced development of neuropathic pain. These findings suggest a link between reduced inflammation in the spinal cord and the pain measures examined in this model. [9].
Applications of ARA-290 peptide
Neuroprotection: ARA 290 has been examined for neuroprotective effects in studies of spinal cord injury, brain injury due to trauma, and ischemic stroke. Endpoints in these studies included neuronal damage and functional recovery.
Cardioprotection: Studies have examined the effects of ARA 290 on ischemia-reperfusion injury, infarct size, and cardiac function, placing it among the cardiovascular peptides studied in experimental models of myocardial infarction.
Protection of the kidneys: In preclinical studies of acute kidney damage and chronic renal failure, ARA 290 has been examined for its effects on the severity of renal damage and on kidney function.
Anti-inflammatory effects: ARA 290 has been studied for anti-inflammatory activity, including effects on the generation of cytokines that promote inflammation and on the resolution of inflammation in various tissues.
In animal models of cutaneous, corneal, and intestinal injuries, ARA 290 has been examined for its effects on wound-closure time and the repair of damaged tissue, including in diabetic neuropathy models.
Several clinical investigations have measured the effects of ARA 290 administration on metabolic control and neuropathic symptoms in trial participants with sarcoidosis and in trial participants with type 2 diabetes mellitus.
Future Research Perspectives on Neuropathy
For the purpose of determining how receiving ARA 290 interacts with targets within cells and refining its pharmacological characteristics, it is essential to have a solid understanding of its tertiary structure. In order to support further research on ARA 290, the characterization of its tertiary structure may provide insights into its reliability, bioavailability, and mechanism of action.
In addition, analyzing the tertiary structure of ARA 290 can be of assistance in the development of analogs with modified particularity and activity. It is crucial to investigate the tertiary structure of ARA 290 in order to evaluate its stability under physiological settings and to make predictions regarding its pharmacokinetic features. By decoding the tertiary structure of ARA 290, we may discover new binding sites and interaction partners, which will allow us to gain a deeper comprehension of the biological roles of this protein.
Early clinical trials have examined ARA 290 in relation to nerve repair. Some studies reported changes in sensory function, pain, and overall quality of life in individuals with neuropathic pain.
On the other hand, more studies are required to characterize study protocols and the long-term effects of ARA 290 on neuron repair in human beings. The continuation of the study into the mechanisms that underlie the neuroprotective and repair-related effects reported for ARA 290 might open new directions in research on nerve injuries and neuropathy illnesses.
When it comes to the study of corneal nerve fiber and neuropathic pain processes with the evaluation of candidate research compounds, the sparing nerve injury (SNI) model has proven to be very helpful. Through the use of the SNI model, a study has been conducted that examined the effects of ARA 290 on neuropathic pain and nerve repair measures.
According to these findings, ARA 290 is a research compound of interest in studies of neuropathic pain that is caused by spinal cord injuries.
References
1. Niesters, M., et al., The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs, 2013. 1(1): p. 77-87.
2. Brines, M. et al., Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences, 2008. 105(31): p. 10925-10930.
3. Winicki, N.M., et al., A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age-associated declines in heart function and prolongs healthspan. Frontiers in Cardiovascular Medicine, 2023. 9: p. 1096887.
4. Brines, M., Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair. Molecular medicine, 2014. 20: p. S10-S16.
5. Pulman, K.G., et al., The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience, 2013. 233: p. 174-183.
6. Swartjes, M., et al., ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular pain, 2014. 10: p. 1744-8069-10-13.
7. Bohr, S., et al., Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. Journal of Molecular Medicine, 2015. 93: p. 199-210.
8. O'Leary, O.E., et al., The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Experimental Eye Research, 2019. 182: p. 144-155.
9. Swartjes, M., et al., Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131). PLoS One, 2013. 8(8): p. e71326.
Read more about peptides
GLP-2TZ: GIP and GLP-1 Dual Receptor Agonist Research
GLP-2TZ is a dual agonist of the GIP and GLP-1 receptors studied in metabolic research. A summary of its structure, receptor pharmacology and published in vitro and rodent findings.

Bacteriostatic Water vs Sterile Water for Reconstituting Lyophilized Research Peptides
Lyophilized research peptides must be brought back into solution before laboratory use. This article compares bacteriostatic water and sterile water, explains the preservative role of benzyl alcohol, and summarizes published research on sterility, storage and stability after reconstitution.